Detailed Information on Publication Record
2020
Ingavirín môže byť sľubnou zlúčeninou v boji proti koronavírusu 2 vyvolávajúcemu ťažký akútny respiračný syndróm (SARS-CoV-2)
MALÍK, Ivan, Gustav KOVÁČ, Tereza PADRTOVÁ and Lucia HUDECOVÁBasic information
Original name
Ingavirín môže byť sľubnou zlúčeninou v boji proti koronavírusu 2 vyvolávajúcemu ťažký akútny respiračný syndróm (SARS-CoV-2)
Name in Czech
Ingavirin může být slibnou sloučeninou v boji proti koronaviru 2 vyvolávajícímu těžký akutní respirační syndrom (SARS-CoV-2)
Authors
MALÍK, Ivan (703 Slovakia, guarantor, belonging to the institution), Gustav KOVÁČ (703 Slovakia), Tereza PADRTOVÁ (203 Czech Republic, belonging to the institution) and Lucia HUDECOVÁ (703 Slovakia)
Edition
Česká a slovesnká farmacie, 2020, 1210-7816
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30107 Medicinal chemistry
Country of publisher
Czech Republic
Confidentiality degree
není předmětem státního či obchodního tajemství
RIV identification code
RIV/00216224:14160/20:00117529
Organization unit
Faculty of Pharmacy
Keywords in English
SARS-CoV-2 • COVID-19 • ingavirin • heterogeneous nuclear ribonucleoproteins • nucleocapsid (N) protein
Tags
Reviewed
Změněno: 3/3/2021 10:52, Mgr. Hana Hurtová
Abstract
V originále
The Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease-19 (COVID-19) pandemic, caused by the virus, have changed the world in just half a year. Lack of effective treatment, coupled with etiology of COVID-19, has resulted in more than 500,000 confirmed deaths at the time of writing, and the global economy is at an unseen unprecedented low level with unknown near- and long-term consequences. Ingavirin has been considered a non-toxic broad-spectrum antiviral with a complex mechanism of action. The molecule was originally designed for the prophylaxis and treatment of flu caused by both Influenza A and B viruses and for the treatment of viral causes of acute respiratory illness. The article hypothesized that the efficiency of given 1H-imidazol-4-yl heterocyclic scaffold-containing compound against SARS-CoV-2 might be connected with its ability to interfere with specific heterogeneous nuclear ribonucleoproteins (A1, for example). These specific cellular RNA-binding proteins showed affinity to Severe Acute Respiratory Coronavirus (SARS-CoV) nucleocapsid (N) protein, which shared high homology with the N protein of SARS-CoV-2 and the fact was expressed by a sequence identity of 90.52%. Impairing of the interactions between nuclear ribonucleoproteins and nucleocapsid (N) protein of SARS-CoV-2 might result in the inhibition of a viral replication cycle. Additional immunomodulating properties of ingavirin could be favorable for induction of adaptive immunity of host cells.